Nexalis Therapeutics has a diversified pipeline of three drug candidates at various stages of clinical development, supported by a total funding facility of $64.6 million.
Our Drug Delivery Platforms
Nexalis Therapeutics leverages two distinct drug delivery modalities to develop innovative therapies for patients with significant unmet medical needs.
Next-Generation Oral Formulations
Our oral drug delivery platform focuses on developing novel formulations that enhance the therapeutic profile of established compounds. SRX-25 combines esketamine with a CYP-450 inhibitor to enable home-use administration for treatment-resistant depression.
- Potential for home-use administration
- FDA 505(b)(2) regulatory pathway
Precision Inhaled Drug-Device
Our proprietary inhaled drug-device combination platform enables rapid-onset delivery of therapeutics directly to the systemic circulation, ideal for conditions requiring immediate relief.
- Rapid onset of action (within minutes)
- Precise dosing via proprietary device
IRX-211
Breakthrough Cancer Pain (BTcP)
Inhaled drug-device combination for rapid-onset relief of Breakthrough Cancer Pain.
Learn MoreIRX-616a
Panic Disorder
Inhaled drug-device combination for rapid intervention in Panic Disorder episodes.
Learn MoreSRX-25
Treatment-Resistant Depression (TRD)
Oral esketamine formulation for Treatment-Resistant Depression with potential for home-use administration.
Learn MoreOur Development Approach
Nexalis Therapeutics focuses on de-risking drug development by leveraging established compounds with known safety profiles. Our programs utilize the FDA 505(b)(2) regulatory pathway where applicable, accelerating development timelines by building on existing safety and efficacy data.
With a total funding facility of $64.6 million from Linlithgow Family Office, we are well-positioned to advance our clinical programs and deliver transformative therapies to patients with significant unmet medical needs.